LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study

Arthritis and Rheumatism

Volumn 48, Issue 2, 2003, Pages 442-454

  Alarcón Segovia, Donato ^a   Tumlin, James A ^b   Furie, Richard A ^c   McKay, James D ^g   Cardiel, Mario H ^a   Strand, Vibeke ^d   Bagin, Robert G ^e   Linnik, Matthew D ^f   Hepburn, Bonnie ^e   Aelion, Jacob ^g   Appel, Gerald B ^g   Aranow, Cynthia ^g   Ballou, Stanley ^g   Becker, Michael ^g   Becker, Nancy J ^g   Belmont, H Michael ^g   Buyon, Jill P ^g   Bohan, Anthony ^g   Brelsford, William G ^g   Carteron, Nancy L ^g   Cronin, Mary E ^g   DeHoratius, Raphael J ^g   Espinoza, Luis R ^g   Genovese, Mark C ^g   Gilkeson, Gary ^g   Gil Aguado, Antonio ^g   Gluck, Oscar ^g   Granda, Jose L ^g   Hill, Maria ^g   Howard, Paul ^g   Ingelmo, Miguel ^g   Kalunian, Kenneth C ^g   Kammer, Gary M ^g   Kanik, Keith ^g   Kaplan, Stanley ^g   Kenney, Howard M ^g   Kurtzman, Neil A ^g   Lahita, Robert G ^g   Liebling, Michael R ^g   Lindberg, Jill Suzanne ^g   Manzi, Susan ^g   Merrill, Joan T ^g   Moreland, Larry W ^g   Neuwelt, C Michael ^g   Petri, Michelle A ^g   Ramsey Goldman, Rosalind ^g   Rosenblatt, Steven G ^g   Rothfield, Naomi ^g   Schousboe, John T ^g   Sewell, K Lea ^g   Sherrer, Yvonne ^g   Smith, Douglas B ^g   Spinowitz, Bruce S ^g   Staub, Roland M ^g   Stern, Steven ^g   Stevenson, Jon T ^g   Van Vollenhoven, Ronald ^g   Varga, John ^g   Vilardell Tarres, Miguel ^g   Wallace, Daniel J ^g   more..

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Santarus Inc   (United States)

^f La Jolla Pharmaceutical Company   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DOUBLE STRANDED DNA; EPITOPE; IMMUNOGLOBULIN G; PREDNISONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ADULT; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; DYSURIA; ECCHYMOSIS; EYE DISEASE; FACE EDEMA; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOKALEMIA; INFECTION; INJURY; INSOMNIA; KIDNEY DISEASE; LUPUS RASH; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; METRORRHAGIA; MIGRAINE; MOUTH ULCER; MULTICENTER STUDY; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; NEPHRITIS; OSTEOARTHRITIS; OTALGIA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PHARYNGITIS; PLEURA DISEASE; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SIDE EFFECT; SINUSITIS; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; TENDON DISEASE; THORAX PAIN; THROMBOEMBOLISM; THRUSH; URINARY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VAGINITIS; VASCULITIS; VASODILATATION; VERTIGO; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ADULT; AUTOANTIBODIES; COMPLEMENT C3; CREATININE; CYCLOPHOSPHAMIDE; DNA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; RECURRENCE; TREATMENT OUTCOME;

EID: 0037331980     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10763     Document Type: Article

References (32)

1. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association with high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977;59:90-6.
2. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg GM. Measurements of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634-43.
3. Swaak AJG, Greenwald J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66.
4. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
5. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
6. Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992;41:1690-700.
7. Ehrenstein MR, Katz DR, Griffiths MH, Papadaki L, Winkler TH, Kalden JR, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995;48:705-11.
8. Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattem of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967;46:1785-94.
9. Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968;161:904-6.
10. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-8.
11. Ebling FM, Hahn BH. Pathogenic subsets of antibodies to DNA. Int Rev Immunol 1989;5:79-95.
12. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui SN, Wilson CB, McConahey PS, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-1215.
13. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in 1980's: a survey of 570 patients. Semin Arthritis Rheum 1991;21:55-64.
14. Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 1985;64:285-95.
15. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus: computer analysis of 520 cases. JAMA 1964;190:104-11.
16. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al, and The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. Clin Exp Rheumatol 1992;10:527-39.
17. Klippel JH. Systemic lupus erythematosus: treatment-related complications superimposed on chronic disease. JAMA 1990;263:1812-5.
18. Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:363-75.
19. Coutts SM, Plunkett ML, Iverson GM, Barstad PA, Berner CM. Pharmacological intervention in antibody mediated disease. Lupus 1996;5:158-9.
20. Weisman MH, Bluestein HO, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314-38.
21. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65.
22. Jones DS, Hachmann JP, Osgood SA, Hayag MS, Barstad PA, Iverson GM, et al. Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem 1994;5:390-9.
23. Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993;72:325-35.
24. Finkelman FD, Holmes JM, Dukhanina OI, Morris SC. Cross-linking of membrane immunoglobulin D, in the absence of T cell help, kills mature B cells in vivo. J Exp Med 1995;181:515-25.
25. Norvell A, Mandik L, Monroe JG. Engagement of the antigenreceptor on immature murine B lymphocytes results in death by apoptosis. J Immunol 1995;154:4404-13.
26. Sem DS, McNeeley PA, Linnik MD. Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies. Arch Biochem Biophys 1999;372:62-8.
27. McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, et al. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 2001;10:526-32.
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
29. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
30. Myszka DG, Jonsen MD, Graves DI. Equilibrium analysis of high-affinity interactions using BIACORE. Anal Biochem 1998;265:326-30.
31. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized clinical trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
32. Alarcón-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.